

Novartis India Limited

Registered Office: Inspire BKC Part of 601 & 701 Bandra Kurla Complex Bandra (East) Mumbai – 400 051 Maharashtra, India Tel +91 22 50243000

Email: india.investors@novartis.com CIN No. L24200MH1947PLC006104

Website: www.novartis.in

Fax +91 22 50243010

June 10, 2022

The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001

Dear Sir/ Madam,

<u>Sub: Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements)</u> <u>Regulations, 2015</u>

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has received following cases pertaining to the issue of duplicate share certificates from Registrar and Transfer Agent on June 09, 2022 and June 10, 2022 respectively:

Folio No	Name of Shareholder	Certificate No.	Distinctive Nos.	No. of Shares
01030078	Usha Bhupendra Dalal Bhupendra Venilal Dalal	441991	144776 - 144871	96
02161923	Lomesh H Shah Anila L Shah	441992	4589238 - 4589327	90

Further, in accordance with the SEBI Notification No. SEBI/LAD-NRO/GN/2022/66 dated January 24, 2022 read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, letter of confirmation(s) in lieu of the physical share certificate(s) will be issued to the said shareholders of the Company within the prescribed timelines.

Request you to take the same on record as required under the provisions of the said Regulation.

Thanking you,

Yours sincerely,

For Novartis India Limited

Malpani Nikhil Digitally signed by Malpani Nikhil DN: dc=com, dc=novartis, ou=people, ou=GR, serialNumber=3079258, cn=Malpani Nikhil Date: 2022.06.10 18:06:53 +05'30'

Nikhil Malpani Company Secretary and Compliance Officer